Kapron

Administer orally with or without food. The suspension should be shaken well before use.

Tranexamic acid acts as an antifibrinolytic by reversibly blocking the lysine binding sites on plasminogen and plasmin, thus preventing their binding to fibrin. This competitive inhibition prevents the conversion of plasminogen to plasmin and inhibits plasmin from degrading fibrin clots, thereby stabilizing the clot and reducing bleeding.

• Hypersensitivity to tranexamic acid
• Active intravascular clotting (e.g., deep vein thrombosis, pulmonary embolism)
• Subarachnoid hemorrhage
• Severe renal impairment (risk of accumulation)
• History of convulsions

Store below 30°C in a dry place, away from direct sunlight. Do not freeze. Keep out of reach of children.

Symptoms may include nausea, vomiting, diarrhea, hypotension, and thromboembolic events. Management is supportive, including symptomatic treatment and maintaining adequate hydration. Hemodialysis may be considered in severe cases.

Pregnancy Category B. Use only if clearly needed. Tranexamic acid is excreted into breast milk; caution should be exercised when administered to a nursing mother.

• Hypersensitivity to tranexamic acid
• Active intravascular clotting (e.g., deep vein thrombosis, pulmonary embolism)
• Subarachnoid hemorrhage
• Severe renal impairment (risk of accumulation)
• History of convulsions

Store below 30°C in a dry place, away from direct sunlight. Do not freeze. Keep out of reach of children.

Symptoms may include nausea, vomiting, diarrhea, hypotension, and thromboembolic events. Management is supportive, including symptomatic treatment and maintaining adequate hydration. Hemodialysis may be considered in severe cases.

Pregnancy Category B. Use only if clearly needed. Tranexamic acid is excreted into breast milk; caution should be exercised when administered to a nursing mother.